An all-oral regimen of daclatasvir, sofosbuvir, and ribavirin (DCV-SOF-RBV) was well tolerated and resulted in a high, sustained virologic response at post-treatment week 12 (SVR12), irrespective of prior hepatitis C virus (HCV) treatment. This according to a study of 50 patients infected with HCV genotype 3 and with advanced liver disease. Researchers found:

• All patients with advanced fibrosis (n=14) achieved SVR12.

• 86% of patients with compensated cirrhosis (n=36) achieved SVR12; 83% in a group treated for 12 weeks and 89% in a group treated for 16 weeks.

• In treatment-experienced patients with cirrhosis, SVR12 rates were 87% overall, 88% among those treated for 12 weeks, and 86% among those treated for 16 weeks.

• 1 patient in the 12-week treatment group died (unrelated to treatment).

• There were 4 relapses, 2 in each treatment group, and no virologic breakthroughs.

• Most common adverse events were insomnia, fatigue, and headache.

• There were no discontinuation for adverse events and no treatment-related serious adverse events.

Citation: Leroy V, Angus P, Bronowicki JP, et al. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+). [Published online ahead of print January 29, 2016]. Hepatology. doi: 10.1002/hep.28473.